Lexaria Bioscience Corp. LEXX 深 滬
已收盤 04-02 16:00:00 美东时间
1.04
+0.174
+20.08%
華盛通- 最 高1.05
- 今 開0.89
- 成交量 66.79万股
- 最 低 0.88
- 昨 收 0.8661
- 總市值 2588.29万
- 52周最高 1.69
- 市盈率 靜 --
- 換手率 2.68%
- 52周最低 0.46
- 委 比 99.68%
- 總股本 2488.74万
- 歷史最高 12.50
- 量 比 3.74
- 振 幅 19.63%
- 歷史最低 0.46
- 每 手 1
- 風險率 0.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) stock rose 48.6% to $0.86 during Thursday's regu...
04-03 01:05
Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company
03-26 21:24
Lexaria Bioscience Launches 2026 R&D Program With Human And Animal GLP-1 Studies To Expand Drug Delivery IP And Business Opportunities
Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in
03-04 22:28
Lexaria Bioscience Results From Human Pilot Study, Comparing DehydraTECH-liraglutide Capsules To Injected Saxenda Branded Liraglutide, Achieves 22.7% Reduction In Adverse Events With DHT-LIR As Compared To SAX-LIR
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which
02-05 22:20
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of Bark Inc (NYSE:BARK) rose sharply in pre-market trading after a 13D f...
01-12 17:34
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
美股大行评级 | 潜在涨幅121.27%！HC Wainwright & Co.：Agios Pharmaceuticals获机构升目标价至62美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Agios Pharmaceuticals"买入"评级，目标价从48美元升至62美元；Leerink Partners：维持Agios Pharmaceuticals"跑赢大市"评级，目标价从34美元升至40美元
2025-12-29 10:27
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.
2025-12-26 19:06
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.
2025-12-24 01:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) stock increased by 6.5% to $0.89 durin...
2025-12-17 05:05
